94. Primary sclerosing cholangitis Clinical trials / Disease details
Clinical trials : 142 / Drugs : 113 - (DrugBank : 37) / Drug target genes : 19 - Drug target pathways : 139
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00325013 (ClinicalTrials.gov) | December 2005 | 10/5/2006 | Evaluation of DHA for the Treatment of PSC | Evaluation of Docosahexaenoic Acid (DHA) for the Treatment of Primary Sclerosing Cholangitis (PSC) | Primary Sclerosing Cholangitis;Colitis | Drug: Docosahexaenoic Acid (DHA) | Beth Israel Deaconess Medical Center | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | 18 Years | 80 Years | Both | 10 | Phase 1 | United States |